Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Nordisk Goes ‘Full-Speed Ahead’ Towards Once-Weekly Basal Insulin

Readouts to all six ONWARDS trials to come in 2022, Development Head Says

Executive Summary

Novo Nordisk’s once-weekly injected basal insulin icodec could be a boon to the many people with type 2 diabetes who are reluctant to start on insulin therapy due to the need for daily injections, the Danish group’s head of development tells Scrip.

You may also be interested in...



Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers

Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.

Roche R&D Spending Surge Reflects In-House Innovation, M&A Prices

A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.

Roche Deals With Huge Gantenerumab Curiosity At H1 Update

Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel